Genscript Biotech Corp is primarily active in the biotechnology industry.

The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.

Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.

Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.

Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.

Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.

Analysts currently set an average price target of 2,67 USD for the Genscript Biotech stock (median: 2,53 USD), implying +77,8 % versus the latest price. The consensus is based on 16 analyst ratings.

Genscript Biotech Analytikerens Kursmål 2026

16 analysts currently rate the Genscript Biotech stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genscript Biotech to generate revenue of 829,78 Mio. USD and earnings per share of 0,02 USD.

Genscript Biotech Analytikerens Kursmål 2026

Converted at the current exchange rate, the Genscript Biotech share trades at 1,30 EUR (1,50 USD).

The Genscript Biotech share (1548.HK) is listed on 4 stock exchanges, including: Frankfurt (G51.F), München (G51.MU).

GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.

forventet-omsætningen for Genscript Biotech er 829,78 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Genscript Biotech er 41,95 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Genscript Biotech er i øjeblikket 77,70. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Genscript Biotech-aktien.

Pris-til-salgs-forholdet (P/S) for Genscript Biotech er i øjeblikket 3,93. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Genscript Biotech-aktien.

AlleAktien-kvalitetsscore for Genscript Biotech er 5/10.

ISIN for Genscript Biotech er KYG3825B1059. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Genscript Biotech er A2ACSB. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Genscript Biotech er 1548.HK. Tickersymbolet bruges til at handle Genscript Biotech-aktier på børsen.

I løbet af de seneste 12 måneder udbetalte Genscript Biotech en dividende på 0,01 USD . Dette svarer til et dividendeafkast på ca. 0,80 %. For de kommende 12 måneder forventes Genscript Biotech at udbetale en dividende på 0,01 USD.

Dividendeudbytteprocenten for Genscript Biotech er i øjeblikket 0,80 %.

Genscript Biotech har udbetalt dividende hvert år i de seneste 0 år.

For de kommende 12 måneder forventes dividender på 0,01 USD. Dette svarer til et dividendeafkast på 0,80 %.

Genscript Biotech er klassificeret i sektoren 'Sundhed'.

For at modtage den seneste dividende fra Genscript Biotech fra på 0,01 USD, skulle du have aktien i din portefølje før ex-datoen den .

Sidste dividende blev udbetalt den .

Dividenderne fra Genscript Biotech udloddes i USD.